GYRE THERAPEUTICS INC (GYRE) Stock News

NASDAQ:GYRE - US4037831033 - Common Stock

7.71 USD

-0.03 (-0.39%)

Last: 9/2/2025, 8:08:04 PM

7.71 USD

0 (0%)

After Hours: 9/2/2025, 8:08:04 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GYRE Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Benzinga - Mentions: NVO MDGL

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

8 days ago - By: Benzinga - Mentions: ACTU CDNA

This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

12 days ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

12 days ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

23 days ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

23 days ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

a month ago - By: Zacks Investment Research - Mentions: ACLX

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: PRTA

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

3 months ago - By: Yahoo Finance - Mentions: DHI CMG

Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

3 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

4 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Zacks Investment Research - Mentions: CLNN

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Gyre Therapeutics Inc.

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications